Stargardt Disease clinical trials at UCSF

2 research studies open to eligible people

Stargardt disease is a genetic eye disorder that causes vision loss. UCSF is studying the drug tinlarebant to see if it works and is safe for treating Stargardt Disease. UCSF is also investigating ACDN-01 given in ascending doses to people with ABCA4-related retinal issues.

Showing trials for

  • Tinlarebant in Subjects With Stargardt Disease

    open to eligible people ages 12-20

    The goal of this clinical trial is to evaluate the safety, tolerability, and efficacy of tinlarebant in subjects with Stargardt Disease

    San Francisco, California and other locations

  • ACDN-01 in ABCA4-related Stargardt Retinopathy (STELLAR)

    open to eligible people ages 18 years and up

    This study is an open-label, single ascending dose clinical trial in participants who have ABCA4-related retinopathies. This is the first-in-human clinical trial in which ACDN-01 will be evaluated for safety, tolerability, and preliminary efficacy following a single subretinal injection of ACDN-01.

    San Francisco, California and other locations

Our lead scientists for Stargardt Disease research studies include .

Last updated: